Zealand Pharma
BiotechDenmark
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
4
Indications↗
Distinct diseases across all programs
49
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 31
Phase 11
By Therapeutic Area
top 2
Gastroenterology
133%
Dermatology
133%
R&D Momentum
47/100
Pipeline Velocity
25/100
Trial Completion Rate
92/100
Pipeline Concentration
33/100
Pipeline Freshness
93/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 10, 2026
Completed
A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
Sep 9, 2026
Completed
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial
Sep 9, 2026
Completed
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
Earlier
Aug 14, 2026TrialA First-in-human, Randomized, Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
Aug 13, 2026TrialA Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)
Aug 4, 2026TrialAn Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
Jul 31, 2026TrialA 104-week, Multicenter, Open-label, Single-arm, Phase 3 Extension Trial Investigating the Long-term Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Rolling Over From the EASE SBS 2 or 3 Trials
Jul 30, 2026TrialAn Interventional, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Efficacy of ZP9830 Administered for 8 Weeks in Participants With Plaque Psoriasis
4 more events
Jul 7, 2026TrialPharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function
Dec 17, 2025TrialInvestigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
Apr 15, 2025TrialPharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
Dec 23, 2024TrialA Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide
Details
Company Info
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology
Dermatology
Plaque Psoriasis
ZP9830Phase 1
Gastroenterology
Regulatory
Regulatory Timeline
20211 event
FDAMar 22
Zegalogue — ZEGALOGUE
Application NDA214231 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)